For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the arrival of Tafamidis and the formulated version represents a genuine change. These innovative therapies stabilize the transthyretin protein, preventing its damaging build-up and lessening the burden of the disease . Individuals are now experien